Methods and compositions for inhibition of dihydroorotate dehydrogenase

Patent metadata

Field	Value
Publication number	US-11999697-B2
Application number	US-202117523675-A
Country	US
Kind code	B2
Filing date	Nov 10, 2021
Priority date	Jun 22, 2018
Publication date	Jun 4, 2024
Grant date	Jun 4, 2024

Abstract

Disclosed herein are compounds, 3,4,6,8-substituted-2-([1,1′-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

First claim

What is claimed:

1. A method for the treatment of a disease or disorder in a mammal comprising the step of administering to the mammal a therapeutically effective amount of at least one compound having a formula represented by a structure:

wherein R 1 is selected from halogen, —SF 5 , —CN, —N 3 , —OH, —NH 2 , —CF 3 , and —CF 2 CF 3 ;
wherein each of R 5b and R 5c is independently selected from —R 20 , hydrogen, halogen, —SF 5 , —CN, —N 3 , —OH, —NH 2 , —CF 3 , and —CF 2 CF 3 ;
wherein R 20 is selected from —C1-C10 alkylamino and —C1-C10 alkoxy; provided that one of R 5b and R 5c is —R 20 ; and
wherein each R 5a , R 5d , and R 5e is independently selected from hydrogen, halogen, —SF 5 , —CN, —N 3 , —OH, —NH 2 , —CF 3 , and —CF 2 CF 3 ;
or a pharmaceutically acceptable salt thereof;
or a pharmaceutical composition thereof comprising the compound and a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the disorder or disease can be treated by inhibition of dihydroorotate dehydrogenase (DHODH) activity.

3. The method of claim 1 , wherein the disorder is a cancer.

4. The method of claim 3 , wherein the cancer is selected from breast cancer, renal cancer, gastric cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, genitourinary tract cancer, lymphatic system cancer, stomach cancer, larynx cancer, lung cancer, bladder cancer, testicular cancer, sarcomas, merkel cell cancer, liver cancer, cervical cancer, endometrial carcinoma, cancer of unknown primary, malignant melanoma, and a hematological cancer.

5. The method of claim 4 , wherein the hematological cancer is leukemia, lymphoma, myeloma, myelodysplastic syndrome, myeloproliferative neoplasm, or mixed myelodysplastic/myeloproliferative syndrome.

6. The method of claim 4 , wherein the hematological cancer is chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), acute lymphoid leukemia (ALL), hairy cell leukemia, chronic myelomonocytic leukemia (CMML), juvenile myelomonocyte leukemia (JMML), large granular lymphocytic leukemia (LGL), acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, Burkett's lymphoma, Hodgkin lymphoma, and non-Hodgkin lymphoma.

7. The method of claim 6 , wherein the hematological cancer is chronic myeloid leukemia (CML) or acute myeloid leukemia (AML).

8. The method of claim 1 , further comprising the step of administering a therapeutically effective amount of at least one agent known to treat a cancer.

9. The method of claim 8 , wherein the at least one agent is selected from a DNA methyltransferase inhibitor, an IDH1-inhibitor, an IDH2 inhibitor, a bcl-2 inhibitor, a MDM2 and/or MDM4 inhibitor, a PI3-kinase inhibitor, an EZH2 inhibitor, a BTK inhibitor, a FLT3 inhibitor, a BRD4 inhibitor, an HDAC-inhibitor, a glucocorticoid, an mTOR inhibitor, a cytotoxic agent, and combinations thereof.

10. The method of claim 9 , wherein the cytotoxic agent is an alkylating agent, an antimetabolite agent, an antineoplastic antibiotic agent, a mitotic inhibitor agent, or other chemotherapeutic agent.

11. The method of claim 1 , wherein the disorder is graft-versus-host disease (GVHD).

12. The method of claim 11 , wherein the GVHD is associated with an organ transplant, an allograft, a xenograft, or a hematopoietic stem cell transplantation.

13. The method of claim 11 , wherein the GVHD is acute GVHD.

14. The method of claim 11 , wherein the GVHD is chronic GVHD.

15. The method of claim 11 , further comprising the step of administering a therapeutically effective amount of at least one agent known to treat GVHD.

16. The method of claim 15 , wherein the least one agent known to treat GVHD is a steroid, an mTor inhibitor, a tyrosine kinase inhibitor, or other agent known to treat GVHD.

17. The method of claim 16 , wherein the steroid is dexamethasone, prednisolone, methylprednisolone, betamethasone, triamicinolone, fludrocortisone, beclomethasone, or combinations thereof; wherein tyrosine kinase inhibitor is imatinib, ruxolitinib, or a combination thereof; wherein the mTor inhibitor is everolimus, sirolimus, temsirolimus, or combinations thereof; or wherein the other agent known to treat GVHD is tacrolimus, clofazimine, psoralen, cyclosporine, alemtuzumab, infliximab, rituximab, etanercept, antithymocyte globulin, thalidomide, mycophenolate mofetil, pentostatin, methotrexate, halofuginone, hydroxychloroquine, ibrutinib, or combinations thereof.

18. The method of claim 1 , wherein the disorder is associated with T-cell proliferation.

19. The method of claim 1 , wherein the disorder is an autoimmune disorder or disease.

20. The method of claim 19 , wherein the autoimmune disorder or disease is selected from lupus, rheumatoid arthritis, ankylosing spondylitis, glomerulonephritis, minimal change disease, ulcerative colitis, crohns disease, addison's disease, adult Still's disease, alopecia areata, autoimmune hepatitis, autoimmune angioedema, Bechet's disease, pemphigoid and variants, celiac disease, chronic inflammatory demyelinating polyneuropathy, churg-Straus syndrome, Crest syndrome, dermatomyositis, neuromyelitis optica, discoid lupus, fibromyalgia, giant cell arteritis, giant cell myocarditis, Goodpasteur's disease, evan's syndrome, autoimmune hemolytic anemia, immune thrombocytopenia, Henoch-Schonlein purpura, IgA nephropathy, IgG4 related sclerosing disease, juvenile arthritis, juvenile diabetes, Kawasaki disease, Leukocytoclastic vasculitis, mixed connective disease, multiple sclerosis, multifocal motor neuropathy, myasthenia gravis, autoimmune neutropenia, optic neuritis, peripheral neuropathy, POEMS syndrome, polymyositis, primary biliary cirrhosis, non-alcoholic hepatosteotosis and associated cirrhosis, psoriasis, scleroderma, sarcoidosis, temporal arteritis, vasculitis, and uveitis.

Assignees

• Ohio State Innovation Foundation
• Hendrix College

Inventors

• Byrd John C
• Goodwin Thomas E
• Elgamal Ola
• Hertlein Erin
• Abdulrahim Mouad
• Bennett Chad E
• Vibhute Sandip Madhukar

Classifications

• C07D215/52 Primary

  with aryl radicals attached in position 2 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/436 Primary

  the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title